Pharmacy Times
JANUARY 1, 2024
Because alcohol is a driver of HIV-associated comorbidities, the reduction interventions may improve the health of people with HIV.
pharmaphorum
JANUARY 1, 2024
Roche has agreed a $295 million deal to buy a point-of-care diagnostics platform from LumiraDx, which recently went into administration
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmacy Times
JANUARY 1, 2024
According to the findings, the use of venetoclax, as well as other new therapies, improved overall survival from 28.6% to 45.3% in non-Hispanic Black patients with AML.
pharmaphorum
JANUARY 1, 2024
A lawsuit in the US is accusing Johnson & Johnson of unlawfully delaying the onset of biosimilar competition to its immunology blockbuster Stelara beyond its US patent expiry date.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmaceutical Technology
JANUARY 1, 2024
In this issue: Pharma’s efforts to curb Scope 3 emissions, understanding European Pharmaceutical legislation, and looking back at the pharma industry’s performance in 2023.
OctariusRx
JANUARY 1, 2024
Happy New Year! New Year’s Day is the first page in a blank book, so let’s write an amazing story! We hope 2023 was a great year for everyone and that 2024 holds success and good fortune in all endeavors you pursue. 2003 was an incredible year for the OctariusRx team and we owe it all to our clients, family, and friends. Thank you for being part of our journey!
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
BioPharm
JANUARY 1, 2024
There are positive indications for future growth.
Dr. Jamie Hardy: The Lifestyle Pharmacist
JANUARY 1, 2024
As we age, maintaining strength and fitness becomes increasingly important for overall health and well-being. Regular exercise, particularly strength training, can help preserve muscle mass, improve bone density, enhance mobility, and boost metabolism. If you’re in your 40s and looking to stay fit and active, incorporating these eight strength exercises into your routine will help you maintain strength, agility, and vitality. 1.
BioPharm
JANUARY 1, 2024
Revolutionary therapies restructure pharmaceutical manufacturing.
BioPharm
JANUARY 1, 2024
GSI shortages result from how hospitals buy GSI drugs, and the underinvestment in manufacturing operations that follow.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
BioPharm
JANUARY 1, 2024
Both adherent and suspension cell culture approaches have their pros and cons, which must be considered for process development.
BioPharm
JANUARY 1, 2024
The authors give an overview of scaling approaches and present good scaling practices for the biopharma industry.
BioPharm
JANUARY 1, 2024
Reviewing regulatory documents, such as 483 forms and Warning Letters, can aid in determining a facility’s inspection readiness, says Siegfried Schmitt, vice president, Technical at Parexel.
BioPharm
JANUARY 1, 2024
Product and process understanding are essential to effective resin selection.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
BioPharm
JANUARY 1, 2024
The success of mRNA-based vaccines paves the way for mRNA in oncology and beyond.
BioPharm
JANUARY 1, 2024
Developing cell-based potency assays for cell therapies requires meticulous coordination.
Expert insights. Personalized for you.
152 
Let's personalize your content